Journal
EXPERT REVIEW OF VACCINES
Volume 11, Issue 9, Pages 1087-1101Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERV.12.84
Keywords
alphavirus; antibody; chikungunya; emergence; evolution; mosquito; vaccine
Categories
Funding
- NIH [AI069145, AI082202, AI093491]
- National Institute of Allergy and Infectious Disease (NIAID) through the Western Regional Center of Excellence for Biodefense and Emerging Infectious Disease Research, NIH [U54 AIO57156]
Ask authors/readers for more resources
In 2004, chikungunya virus (CHIKV) re-emerged from East Africa to cause devastating epidemics of debilitating and often chronic arthralgia that have affected millions of people in the Indian Ocean Basin and Asia. More limited epidemics initiated by travelers subsequently occurred in Italy and France, as well as human cases exported to most regions of the world, including the Americas where CHIKV could become endemic. Because CHIKV circulates during epidemics in an urban mosquito-human cycle, control of transmission relies on mosquito abatement, which is rarely effective. Furthermore, there is no antiviral treatment for CHIKV infection and no licensed vaccine to prevent disease. Here, we discuss the challenges to the development of a safe, effective and affordable chikungunya vaccine and recent progress toward this goal.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available